Company Overview - Kyowa Kirin, Inc. is a wholly owned subsidiary of Kyowa Kirin Co. Ltd, focused on developing solutions for rare diseases, particularly in oncology [1][5] - The company has over 70 years of experience in drug discovery and biotechnology innovation, aiming to deliver novel medicines and treatments with life-changing value [7] Industry Context - Cutaneous T-cell lymphoma (CTCL) is a rare form of blood cancer that primarily affects the skin, with Mycosis Fungoides (MF) and Sézary Syndrome (SS) being the most common subtypes [2][6] - Diagnosis of CTCL can be challenging, often taking patients 2-7 years to receive an accurate diagnosis, which can lead to worse prognoses [2][5] Product Launch - Kyowa Kirin has launched a new staging tool for healthcare providers to assist in the accurate staging of patients with MF and SS, available on PROBEinCTCL.com [1][5] - The tool simplifies the staging process by using up to 20 Yes/No questions and real clinical case imagery, guiding users through the TNMB system [3][4] Clinical Relevance - The staging tool is designed to enhance clinical judgment by translating complex guidelines into a practical assessment, thereby supporting more consistent and informed care [2][3] - The tool is based on established guidelines from the National Comprehensive Cancer Network and recommendations from various oncology organizations [4]

Core Insights - The KOMET-007 trial demonstrated encouraging clinical activity for ziftomenib in combination with 7+3 for newly diagnosed NPM1-m and KMT2A-r AML patients, showing high rates of complete remission and minimal residual disease negativity [1][2][4] Group 1: Clinical Data - In the KOMET-007 trial, 93% (41/44) of NPM1-m patients and 89% (24/27) of KMT2A-r patients achieved complete remission composite (CRc) [1] - Among responding patients, 71% (24/34) of NPM1-m and 88% (14/16) of KMT2A-r patients achieved measurable residual disease (MRD) negativity [1] - The median follow-up times were 24.9 weeks for NPM1-m patients and 15.7 weeks for KMT2A-r patients, with 96% (47/49) of NPM1-m and 88% (29/33) of KMT2A-r patients remaining alive [3] Group 2: Safety and Tolerability - The safety profile of ziftomenib was consistent with previous data, with Grade 3 adverse events occurring in over 10% of patients, including febrile neutropenia (15%) and decreased platelet count (15%) [4] - No dose-limiting toxicities or additive myelosuppression were observed, indicating a favorable safety profile for ziftomenib [4] Group 3: Future Developments - Kura Oncology plans to initiate the KOMET-017-IC and NIC Phase 3 studies in the second half of 2025 to further evaluate ziftomenib's efficacy in AML treatment [1][5] - A virtual investor event is scheduled for June 18, 2025, to discuss the results and broader development plans for ziftomenib [6] Group 4: Company Background - Kura Oncology is focused on developing precision medicines for cancer, with ziftomenib being the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for R/R NPM1-m AML [7] - Kyowa Kirin, a partner in the development of ziftomenib, has a long history in drug discovery and biotechnology innovation, aiming to address high unmet medical needs [9]

Core Viewpoint - The research service "Asia Value & Moat Stocks" targets value investors looking for Asia-listed stocks that exhibit a significant disparity between market price and intrinsic value, focusing on deep value balance sheet bargains and wide moat stocks [1] Group 1: Investment Focus - The service emphasizes deep value balance sheet bargains, which include net cash stocks, net-nets, low price-to-book (P/B) stocks, and sum-of-the-parts discounts [1] - It also highlights wide moat stocks, which are characterized by strong earnings power at a discount, including high-quality businesses and hidden champions [1] Group 2: Market Emphasis - The primary focus of the investment ideas is on the Hong Kong market, providing a range of watch lists with monthly updates for investors [1]

Core Viewpoint - The comparison between Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD) indicates that KNBWY is currently a more attractive option for value investors due to its stronger earnings outlook and favorable valuation metrics [1][3][7]. Valuation Metrics - KNBWY has a forward P/E ratio of 12.22, while BUD has a forward P/E of 16.67, suggesting KNBWY is undervalued compared to BUD [5]. - The PEG ratio for KNBWY is 0.95, indicating better expected EPS growth relative to its price, whereas BUD has a PEG ratio of 1.93 [5]. - KNBWY's P/B ratio is 1.10, compared to BUD's P/B of 1.20, further supporting KNBWY's valuation advantage [6]. Investment Grades - KNBWY holds a Zacks Rank of 2 (Buy), while BUD has a Zacks Rank of 3 (Hold), reflecting a more favorable earnings estimate revision trend for KNBWY [3]. - KNBWY has earned a Value grade of A, while BUD has a Value grade of C, indicating KNBWY is perceived as a better value investment [6].

Core Viewpoint - The article emphasizes the importance of value investing and highlights Kirin (KNBWY) as a strong candidate for value investors due to its favorable valuation metrics [2][5]. Valuation Metrics - Kirin (KNBWY) has a Zacks Rank of 2 (Buy) and a Value grade of A, indicating it is a high-quality value stock [3]. - The stock is currently trading at a P/E ratio of 12.35, which is lower than the industry average of 14.97 [3]. - KNBWY's Forward P/E has fluctuated between 11.06 and 14.14 over the past 12 months, with a median of 12.56 [3]. - The P/S ratio for KNBWY is 0.72, compared to the industry average of 1.31, suggesting it is undervalued based on sales [3]. - The P/CF ratio for KNBWY is 10.89, significantly lower than the industry average of 42.52, indicating a strong cash outlook [4]. Investment Outlook - The combination of these metrics suggests that Kirin is likely undervalued, making it an attractive option for value investors [5].

Core Insights - Kyowa Kirin Co., Ltd. announced the presentation of Phase 3 ROCKET HORIZON trial results for rocatinlimab, targeting OX40 receptor in moderate-to-severe atopic dermatitis, at the AAD 2025 Annual Meeting [1][2] Group 1: Clinical Trial Details - ROCKET HORIZON is a Phase 3, randomized, placebo-controlled, double-blind trial involving 726 adult patients, assessing the efficacy, safety, and tolerability of rocatinlimab administered subcutaneously every four weeks for 24 weeks [3] - Co-primary endpoints include achieving a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 or 1 with a ≥ 2-point reduction from baseline at week 24, and a ≥ 75% reduction from baseline in Eczema Area and Severity Index score (EASI-75) at week 24 [3] - Key secondary endpoints focus on the impact of rocatinlimab on itch, safety, and tolerability [3] Group 2: Atopic Dermatitis Overview - Atopic dermatitis is a chronic inflammatory disease affecting 15-20% of children and up to 10% of adults, characterized by excessively dry, itchy skin and unpredictable flare-ups [4] - T-cell imbalance is identified as a root cause of atopic dermatitis, contributing to its clinical manifestations [4] Group 3: Rocatinlimab Overview - Rocatinlimab is an anti-OX40 receptor human monoclonal antibody under investigation for moderate-to-severe atopic dermatitis, as well as for moderate to severe uncontrolled asthma and prurigo nodularis [5] - The antibody was discovered through collaboration between Kyowa Kirin and La Jolla Institute for Immunology [5] Group 4: Collaboration with Amgen - Kyowa Kirin and Amgen entered a collaboration agreement on June 1, 2021, for the joint development and commercialization of rocatinlimab, with Amgen leading the global development except in Japan [6] - If approved, both companies will co-promote rocatinlimab in the United States, with Kyowa Kirin having opt-in rights for co-promotion in select markets [6]

Core Insights - The article compares Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD) to determine which stock is more attractive for value investors [1] Valuation Metrics - Kirin Holdings Co. has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Anheuser-Busch Inbev has a Zacks Rank of 4 (Sell) [3] - KNBWY has a forward P/E ratio of 11.30, compared to BUD's forward P/E of 14.37, suggesting KNBWY is undervalued [5] - KNBWY's PEG ratio is 0.88, while BUD's PEG ratio is 1.66, indicating KNBWY has a better expected earnings growth relative to its price [5] - KNBWY has a P/B ratio of 1.01, slightly lower than BUD's P/B of 1.03, further supporting KNBWY's valuation advantage [6] - Based on these metrics, KNBWY holds a Value grade of A, while BUD has a Value grade of C, reinforcing KNBWY as the superior value option [6]

Core Viewpoint - The article emphasizes the importance of value investing as a successful strategy across various market conditions, highlighting the use of fundamental analysis and valuation metrics to identify undervalued stocks. Group 1: Value Investing Strategy - Value investing is a popular stock market trend that focuses on identifying stocks believed to be undervalued by the market through fundamental analysis and traditional valuation metrics [2] - Zacks has developed a Style Scores system to identify stocks with specific traits, particularly in the "Value" category, which is of interest to value investors [3] Group 2: Kirin (KNBWY) Analysis - Kirin (KNBWY) has a Zacks Rank of 2 (Buy) and an A grade for Value, indicating it is a strong candidate for value investors [4] - The stock is currently trading at a P/E ratio of 11.29, significantly lower than its industry's average of 13.82, suggesting it may be undervalued [4] - KNBWY has a P/S ratio of 0.67, compared to the industry's average P/S of 1.27, further indicating its potential undervaluation [5] - The combination of these metrics positions Kirin as one of the market's strongest value stocks, especially considering its positive earnings outlook [6]

Core Insights - AlphaMeld Corporation has announced the continuation and expansion of its collaboration with Kyowa Kirin Co., Ltd., enhancing access to its AI-powered AlphaMeld® platform for drug discovery and development [1][2][4] Group 1: Collaboration Details - The expanded partnership allows Kyowa Kirin's global research and development teams to integrate the AlphaMeld platform into their workflows, facilitating data-driven decisions and streamlining the drug development process [4][5] - This collaboration builds on previous successes and highlights Kyowa Kirin's commitment to leveraging advanced AI technologies to address unmet medical needs globally [2][3] Group 2: Technological Impact - The AlphaMeld platform empowers stakeholders involved in early drug discovery, target identification, competitive intelligence, and clinical trial optimization by extracting actionable insights from diverse datasets [2][4] - The integration of the AlphaMeld platform is expected to enable Kyowa Kirin to identify novel therapeutic opportunities with increased speed, precision, and probability of clinical success [5][6] Group 3: Company Backgrounds - AlphaMeld Corporation is a leader in applying AI, machine learning, and generative AI tools to revolutionize drug discovery, with a mission to expedite transformative therapies for diseases with unmet medical needs [6] - Kyowa Kirin has over 70 years of experience in drug discovery and biotechnology innovation, focusing on developing next-generation therapies for high unmet medical needs [7]

Core Insights - Kirin Holdings Co. (KNBWY) is currently rated higher than Diageo (DEO) based on Zacks Rank, with KNBWY at 2 (Buy) and DEO at 4 (Sell) [3] - KNBWY exhibits stronger earnings estimate revision activity compared to DEO, indicating a more favorable analyst outlook for KNBWY [3][7] Valuation Metrics - KNBWY has a forward P/E ratio of 11.13, significantly lower than DEO's forward P/E of 18.80, suggesting KNBWY is undervalued [5] - The PEG ratio for KNBWY is 0.86, while DEO's PEG ratio is considerably higher at 4.21, indicating KNBWY's expected earnings growth is more favorable relative to its valuation [5] - KNBWY's P/B ratio stands at 1, compared to DEO's P/B ratio of 5.73, further supporting the notion that KNBWY is undervalued [6] Value Grades - KNBWY holds a Value grade of A, while DEO has a Value grade of F, highlighting KNBWY's superior valuation metrics [6]